-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Pfizer Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$41.91 B | $81.29 B | $100.33 B | $58.50 B | $63.63 B |
| Cost of Revenue |
|
$8.69 B | $30.82 B | $34.34 B | $29.69 B | $16.42 B |
| Gross Profit |
|
$33.22 B | $50.47 B | $65.99 B | $28.81 B | $47.21 B |
| Research & Development |
|
$9.41 B | $13.83 B | $11.43 B | $10.68 B | $10.82 B |
| Selling,General & Administrative |
|
$11.62 B | $12.70 B | $13.68 B | $14.77 B | $14.73 B |
| Operating Expense |
|
$24.46 B | $30.23 B | $28.71 B | $25.45 B | $25.55 B |
| Operating Income |
|
$10.63 B | $24.83 B | $40.03 B | $3.36 B | $14.94 B |
| Net Income |
|
$7.02 B | $21.98 B | $31.37 B | $2.12 B | $8.03 B |
Pfizer Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$12.22 B | $31.07 B | $22.73 B | $12.69 B | $20.48 B |
| Inventories |
|
$8.05 B | $9.06 B | $8.98 B | $10.19 B | $10.85 B |
| Total Current Assets |
|
$35.07 B | $59.69 B | $51.26 B | $43.33 B | $50.36 B |
| Property,Plant and Equipment |
|
$13.90 B | $14.88 B | $16.27 B | $21.86 B | $18.39 B |
| Goodwill |
|
$49.58 B | $49.21 B | $51.38 B | $67.78 B | $68.53 B |
| Total Assets |
|
$154.23 B | $181.48 B | $197.21 B | $226.50 B | $213.40 B |
| Total Liabilities |
|
$90.76 B | $104.01 B | $101.29 B | $137.21 B | $124.90 B |
| Retained Earnings |
|
$96.77 B | $103.39 B | $125.66 B | $118.35 B | $116.73 B |
| Total Shareholder Equity |
|
$63.24 B | $77.20 B | $95.66 B | $89.01 B | $88.20 B |
| Common Stock |
|
$470.00 M | $473.00 M | $476.00 M | $478.00 M | $480.00 M |
Pfizer Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$4.78 B | $5.19 B | $5.06 B | $6.29 B | $7.01 B |
| Dividends Payout |
|
-$8.44 B | -$8.73 B | -$8.98 B | -$9.25 B | -$9.51 B |
| Capital Expenditures (Capex) |
|
-$2.79 B | -$2.71 B | -$3.24 B | -$3.91 B | -$2.91 B |
| Free Cash Flow (FCF) |
|
$11.61 B | $29.87 B | $26.03 B | $4.79 B | $9.84 B |
Pfizer Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$33.22 B | $50.47 B | $65.99 B | $28.81 B | $47.21 B |
| Gross Profit Margin (%) |
|
79.26% | 62.08% | 65.77% | 49.25% | 74.19% |
| Operating Income |
|
$10.63 B | $24.83 B | $40.03 B | $3.36 B | $14.94 B |
| Operating Income Margin (%) |
|
25.37% | 30.55% | 39.90% | 5.74% | 23.48% |
| Net Income |
|
$7.02 B | $21.98 B | $31.37 B | $2.12 B | $8.03 B |
| Net Income Margin (%) |
|
16.75% | 27.04% | 31.27% | 3.62% | 12.62% |
| EBITDA |
|
$13.17 B | $30.79 B | $41.03 B | $9.56 B | $18.13 B |
| EBITDA Margin (%) |
|
31.42% | 37.88% | 40.90% | 16.34% | 28.49% |
Pfizer Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
11.10% | 28.47% | 32.79% | 2.38% | 9.11% |
| Return on Assets (ROA) |
|
4.55% | 12.11% | 15.91% | 0.94% | 3.76% |
| Debt to Equity |
|
60.52% | 47.92% | 36.45% | 79.59% | 72.16% |
| Debt to total asset |
|
24.82% | 20.39% | 17.68% | 31.28% | 29.83% |
| Enterprise value to revenue |
|
5.75 | 4.50 | 3.21 | 3.94 | 3.35 |
| Enterprise value to EBITDA |
|
18.30 | 11.88 | 7.84 | 24.11 | 11.74 |
| Enterprise value |
|
$240.97 B | $365.79 B | $321.81 B | $230.45 B | $212.87 B |
| Cash to Debt |
|
37.63% | 88.06% | 83.93% | 12.28% | 20.02% |
| Tax Rate (%) |
|
6.36% | 7.62% | 9.58% | -105.29% | -0.35% |
| Payout Ratio |
|
120.23% | 39.72% | 28.63% | 436.39% | 118.44% |
